SCHEMBL464983

SCHEMBL464983

C=CCON1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28036052 0.98 MAPT (0.36) MAPTMAPK1ALDH1A1
SCHEMBL1754856 0.97
SCHEMBL15825944 0.76 KDM4E (0.39) ALDH1A1
SCHEMBL2923420 0.74
SCHEMBL8850067 0.73 GPR119 (0.31)
SCHEMBL12374748 0.71
SCHEMBL12374739 0.71
SCHEMBL22093047 0.70
SCHEMBL10337202 0.70 LPAR3 (0.39) MAPTALDH1A1
SCHEMBL9289027 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129107-A1 HYDROSILYLATION PROCESS PHOTOCATALYSED BY A MANGANESE COMPLEX CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2025-04-24 US claimed
CN-119343356-A Hydrosilylation process by manganese complex photocatalysis 埃肯有机硅法国简易股份公司 2025-01-21 CN claimed
EP-2935287-B1 METHOD FOR THE HYDROSILYLATION OF A SILOXANE PHOTOCATALYSED BY A POLYOXOMETALATE COMPOUND BLUESTAR SILICONES FRANCE (FR) 2016-12-14 EP claimed
US-9475829-B2 Method for the hydrosilylation of a siloxane photocatalysed by a polyoxometalate compound BLUESTAR SILICONES FRANCE SAS (FR) 2016-10-25 US claimed
US-20150315214-A1 METHOD FOR THE HYDROSILYLATION OF A SILOXANE PHOTOCATALYSED BY A POLYOXOMETALATE COMPOUND BLUESTAR SILICONES FRANCE SAS (FR) 2015-11-05 US claimed
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US claimed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US claimed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US claimed
EP-2035427-A2 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST Mitsubishi Tanabe Pharma Corporation (JP) 2009-03-18 EP claimed
WO-2008004698-A2 PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-01-10 WO claimed
US-20040224967-A1 Phenylaminopyrimidine derivatives and methods of use CHEN GUOQING P 2004-11-11 US claimed
US-20250129107-A1 HYDROSILYLATION PROCESS PHOTOCATALYSED BY A MANGANESE COMPLEX CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2025-04-24 US disclosed
CN-119343356-A Hydrosilylation process by manganese complex photocatalysis 埃肯有机硅法国简易股份公司 2025-01-21 CN disclosed
US-20240287255-A1 HYDROSILYLATION METHOD CATALYSED BY AN IRON COMPLEX CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-08-29 US disclosed
EP-3354688-B1 POLYACETAL RESIN COMPOSITION AND MOLDED BODY THEREOF ASAHI CHEMICAL IND (JP) 2024-03-13 EP disclosed
EP-0244027-A2 Process for the synthesis of allylated derivatives of 2,2,6,6-tetraalkylpiperidinols ENICHEM SYNTHESIS S.p.A. (IT) 1987-11-04 EP disclosed
US-4329352-A ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1982-05-11 US disclosed
US-4329352-A ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1982-05-11 US disclosed
US-4315939-A Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, pharmaceutical formulations containing these compounds and use in treating cardiac arrhythmias BASF AKTIENGESELLSCHAFT (DE) 1982-02-16 US disclosed
US-4315939-A Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, pharmaceutical formulations containing these compounds and use in treating cardiac arrhythmias BASF AKTIENGESELLSCHAFT (DE) 1982-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR MAPT 4458/4885MAPK1 508/4885ALDH1A1 2507/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR MAPT 4396/4885MAPK1 524/4885ALDH1A1 2256/4885
US-20250129107-A1 HYDROSILYLATION PROCESS PHOTOCATALYSED BY A MANGANESE COMPLEX C9, PIEZO1, HMOX1 MAPT 4246/4885MAPK1 2928/4885ALDH1A1 548/4885
US-20150315214-A1 METHOD FOR THE HYDROSILYLATION OF A SILOXANE PHOTOCATALYSED BY A POLYOXOMETALATE COMPOUND HAO2, HAAO, PPOX MAPT 3848/4885MAPK1 4531/4885ALDH1A1 686/4885
US-20040224967-A1 Phenylaminopyrimidine derivatives and methods of use ABL1, ABL2, LCK MAPT 1427/4885MAPK1 405/4885ALDH1A1 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.